Indian Trade and Industry minister Anand Sharma holds on April 8, 2013 a press conference in Geneva after his keynote address at the World Intellectual Property Organization (WIPO) on the occasion of India's accession to the Madrid Protocol. Sharma delivered remarks on the recent rejection by India's Supreme Court of a patent bid by Swiss drug giant Novartis.
This population represents a large and therefore potentially lucrative market segment for drug developers ... The majority of hormonal therapies used to treat patients in this population are generic, and market dynamics had been stagnating until last year's approval of everolimus (Novartis's Afinitor) in this population. Uptake of everolimus and the development of promising late-stage clinical prospects such as palbociclib and buparlisib are set to reinvigorate this market segment.
In that way Novartis could drip feed the stake away, and Roche would be able to drip their buyback into the market.
If Roche can buy this stake it's more positive for them than it is for Novartis, in terms of leverage on earnings. It's accretive for Novartis, but very accretive for RocheMore quotes »
Farmaceutica pierde batalla de patentes en India
verdaderas invenciones, no a medicamentos a los que se hagan cambios menores", manifesto Singh a la prensa afuera de la corte.Novartis dijo que el fallo es "un reves para los enfermos", pues la proteccion de patentes es fundamental para fomentar la inversion Read more »
Drug maker Novartis loses India patent battle
the drug did not merit intellectual property protection in India because it was not a new medicine. In response to the ruling, Novartis said it would not invest in drug research in India.The court's decision has global significance since India's $26 billion Read more »
Around the web
Pfizer Stock Checkup for May
quite different despite some similarities. For example, J&J operates a much larger consumer products group than Pfizer does. Novartis' business units include Alcon, which focuses on vision care products -- an area for which Pfizer has no equivalent. Likewise, 2:28 PM from Daily Finance Read more »
Array BioPharma's CEO Presents at 2013 UBS Global Life Sciences Conference (Transcript)
populations very broadly active agent, we’re very unfortunate to have two great molecules in the mix here. I’ll start with Novartis, Novartis is one of our partners, economics with Novartis are very healthy meaning then in the U.S. especially we expect a high 1:29 PM from Seeking Alpha Read more »
Novartis: Largest-ever global -2-
members. This is a community that has different physical and emotional needs from those living with early stage breast cancer. Novartis Oncology has collaborated with leading members of the global advocacy community to create the program and corresponding 2:39 AM from premium presse 5 Read more »
Astex Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 03:30 PM
I'll go over as well. And our relationships include Eisai and Janssen, of course, with regard to Dacogen, then also AstraZeneca, Novartis and GSK relative to a number of other drugs that are in our portfolio. Five partner-funded programs are in Phase I and 5/20/13 from Seeking Alpha Read more »
Three Reasons Actavis Is Buying Warner Chilcott
while Actavis has been at the centre of recent M&A speculation – with Valeant Pharmaceuticals, Mylan and at one stage, Novartis and Teva, cited as interested parties – it was always a deal with Warner Chilcott that made most strategic sense. Actavis has been from Forbes Read more »